YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay

Chronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1...

Full description

Bibliographic Details
Main Authors: Yaqin Tang, Zhiwei Li, Hongqin Yang, Yang Yang, Chi Geng, Bin Liu, Tiantian Zhang, Siyang Liu, Yunfei Xue, Hongkai Zhang, Jing Wang, Hongmei Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.945557/full
_version_ 1828428865756725248
author Yaqin Tang
Zhiwei Li
Hongqin Yang
Yang Yang
Chi Geng
Bin Liu
Tiantian Zhang
Siyang Liu
Yunfei Xue
Hongkai Zhang
Jing Wang
Hongmei Zhao
author_facet Yaqin Tang
Zhiwei Li
Hongqin Yang
Yang Yang
Chi Geng
Bin Liu
Tiantian Zhang
Siyang Liu
Yunfei Xue
Hongkai Zhang
Jing Wang
Hongmei Zhao
author_sort Yaqin Tang
collection DOAJ
description Chronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1 (YB1) is an RBP that has participated in many inflammatory diseases. Here, we found an increased expression of phosphorylated YB1 (pYB1) in atherosclerotic plaques and demonstrated that YB1 dephosphorylation reduced lipid accumulation and lesion area in the aorta in vivo. Additionally, we found that inflammatory cytokines were downregulated in the presence of YB1 dephosphorylation, particularly CCL2, which participates in the pathogenesis of atherosclerosis. Furthermore, we demonstrated that CCL2 mRNA rapid degradation was mediated by the glucocorticoid receptor-mediated mRNA decay (GMD) process during YB1 dephosphorylation, which resulted in the downregulation of CCL2 expression. In conclusion, YB1 phosphorylation affects the development of atherosclerosis through modulating inflammation, and targeting YB1 phosphorylation could be a potential strategy for the treatment of atherosclerosis by anti-inflammation.
first_indexed 2024-12-10T17:24:09Z
format Article
id doaj.art-12a2fe87067d4929bcff8cd7ba7ea999
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-12-10T17:24:09Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-12a2fe87067d4929bcff8cd7ba7ea9992022-12-22T01:39:53ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-08-01910.3389/fcvm.2022.945557945557YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decayYaqin Tang0Zhiwei Li1Hongqin Yang2Yang Yang3Chi Geng4Bin Liu5Tiantian Zhang6Siyang Liu7Yunfei Xue8Hongkai Zhang9Jing Wang10Hongmei Zhao11State Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaJilin Zhongtai Biotechnology Co., Ltd, Jilin, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaThe Pathology Department, Beijing Hospital of Traditional Chinese Medicine, The Capital Medical University, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, ChinaChronic inflammation is a key pathological process in atherosclerosis. RNA binding proteins (RBPs) have been reported to play an important role in atherosclerotic plaque formation, and they could regulate the expression of inflammatory factors by phosphorylation modification. Y-box binding protein 1 (YB1) is an RBP that has participated in many inflammatory diseases. Here, we found an increased expression of phosphorylated YB1 (pYB1) in atherosclerotic plaques and demonstrated that YB1 dephosphorylation reduced lipid accumulation and lesion area in the aorta in vivo. Additionally, we found that inflammatory cytokines were downregulated in the presence of YB1 dephosphorylation, particularly CCL2, which participates in the pathogenesis of atherosclerosis. Furthermore, we demonstrated that CCL2 mRNA rapid degradation was mediated by the glucocorticoid receptor-mediated mRNA decay (GMD) process during YB1 dephosphorylation, which resulted in the downregulation of CCL2 expression. In conclusion, YB1 phosphorylation affects the development of atherosclerosis through modulating inflammation, and targeting YB1 phosphorylation could be a potential strategy for the treatment of atherosclerosis by anti-inflammation.https://www.frontiersin.org/articles/10.3389/fcvm.2022.945557/fullatherosclerosisRNA binding proteinphosphorylationinflammationmRNA decay
spellingShingle Yaqin Tang
Zhiwei Li
Hongqin Yang
Yang Yang
Chi Geng
Bin Liu
Tiantian Zhang
Siyang Liu
Yunfei Xue
Hongkai Zhang
Jing Wang
Hongmei Zhao
YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
Frontiers in Cardiovascular Medicine
atherosclerosis
RNA binding protein
phosphorylation
inflammation
mRNA decay
title YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_full YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_fullStr YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_full_unstemmed YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_short YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay
title_sort yb1 dephosphorylation attenuates atherosclerosis by promoting ccl2 mrna decay
topic atherosclerosis
RNA binding protein
phosphorylation
inflammation
mRNA decay
url https://www.frontiersin.org/articles/10.3389/fcvm.2022.945557/full
work_keys_str_mv AT yaqintang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT zhiweili yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT hongqinyang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT yangyang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT chigeng yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT binliu yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT tiantianzhang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT siyangliu yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT yunfeixue yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT hongkaizhang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT jingwang yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay
AT hongmeizhao yb1dephosphorylationattenuatesatherosclerosisbypromotingccl2mrnadecay